echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Horizon Therapeutics' thyroid eye disease drug Tepezza enters Phase 4 clinical trials

    Horizon Therapeutics' thyroid eye disease drug Tepezza enters Phase 4 clinical trials

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Horizon Therapeutics recently announced that a Phase 4 clinical trial (NCT04583735) evaluating the efficacy and safety of Tepezza (teprotumumab) in the treatment of chronic (inactive) thyroid eye disease (TED) has enrolled the first patient


    Tepezza is the first and only drug approved by the US FDA for the treatment of TED.


    TED begins in the acute (active) phase, during which the signs and symptoms of inflammation, such as eye pain, swelling, exophthalmos (eyeball), and diplopia, progress over time


    This randomized, double-blind, placebo-controlled, parallel-group, multi-center Phase 4 trial will evaluate the efficacy, safety and tolerability of Tepezza and placebo in the treatment of chronic TED patients


    The primary efficacy endpoint is the change from baseline in exophthalmos (eyeball) in the study eye at week 24


    Thyroid ophthalmopathy (TED) is a progressive and debilitating autoimmune disease.


    Active TED lasts up to 3 years and is characterized by inflammation and tissue expansion behind the eye


    In the past, patients had to go through active TED until the disease became inactive (which usually left permanent and visually impaired consequences) before performing complex and expensive surgery, but surgery may never restore vision or appearance


    Tepezza’s active pharmaceutical ingredient, teprotumumab, is a fully human IgG1 monoclonal antibody that targets insulin-like growth factor-1 receptor (IGF-1R).


    Note: The original text has been deleted

    Original source: Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.